{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:34:58Z","timestamp":1791167698750,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.cgh.2014.07.058","type":"journal-article","created":{"date-parts":[[2014,8,10]],"date-time":"2014-08-10T06:45:12Z","timestamp":1407653112000},"page":"302-309.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["The Benefit-to-Risk Balance of Combining Infliximab With Azathioprine Varies With Age: A Markov Model"],"prefix":"10.1016","volume":"13","author":[{"given":"Frank I.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravy K.","family":"Vajravelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Bewtra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2014.07.058_bib1","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2014.07.058_bib2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial","volume":"130","author":"Lemann","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.07.058_bib3","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2014.07.058_bib4","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","article-title":"American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease","volume":"145","author":"Terdiman","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.07.058_bib5","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2014.07.058_bib6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/ajg.2012.406","article-title":"Increased risk of pneumonia among patients with inflammatory bowel disease","volume":"108","author":"Long","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2014.07.058_bib7","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/ajg.2011.283","article-title":"Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease","volume":"106","author":"Herrinton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2014.07.058_bib8","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2014.07.058_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","volume":"8","author":"Long","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2014.07.058_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/pds.2216","article-title":"The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006","volume":"21","author":"Herrinton","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cgh.2014.07.058_bib11","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2003-05-1675","article-title":"Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients","volume":"102","author":"Belhadj","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cgh.2014.07.058_bib12","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jamcollsurg.2012.01.044","article-title":"Predictive factors of early bowel obstruction in colon and rectal surgery: data from the Nationwide Inpatient Sample, 2006-2008","volume":"214","author":"Masoomi","year":"2012","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.cgh.2014.07.058_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Cottone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2014.07.058_bib14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(00)70353-2","article-title":"Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma","volume":"118","author":"Lewis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.07.058_bib15","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/j.1572-0241.2008.01836.x","article-title":"Immunosuppressant medications and mortality in inflammatory bowel disease","volume":"103","author":"Lewis","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2014.07.058_bib16","unstructured":"Arias E. National vital statistics reports. United States Life Tables, 2007 2011;59:1\u201361."},{"key":"10.1016\/j.cgh.2014.07.058_bib17","unstructured":"Howlader N, Noone A, Krapcho M, et\u00a0al. SEER cancer statistics review, 1975-2010. Available at: http:\/\/seer.cancer.gov\/csr\/1975_2010\/. Accessed April 2013."},{"key":"10.1016\/j.cgh.2014.07.058_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00054725-199712000-00004","article-title":"An evaluation of utility measurement in Crohn\u2019s disease","volume":"3","author":"Gregor","year":"1997","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.07.058_bib19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2014.07.058_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.07.058_bib21","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S1873-9946(14)60099-4","article-title":"Adalimumab monotherapy versus combination therapy with adalimumab and immunomodulators for Crohn's disease: a meta-analysis","volume":"8","author":"Kopylov","year":"2014","journal-title":"J\u00a0Crohn's Colitis"},{"key":"10.1016\/j.cgh.2014.07.058_bib22","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/S0016-5085(13)60637-X","article-title":"Impact of concomitant immunomodulator treatment on efficacy and safety of anti-TNF therapy in Crohn's disease: a meta-analysis of placebo controlled trials with individual patient-level data","volume":"144","author":"Jones","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.07.058_bib23","doi-asserted-by":"crossref","first-page":"S773","DOI":"10.1016\/S0016-5085(11)63209-5","article-title":"Safety of infliximab and other Crohn's disease therapies: Treat\u2122 registry data with a mean of 5 years of follow-up","volume":"140","author":"Lichtenstein","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.07.058_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ajh.21655","article-title":"Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis","volume":"85","author":"Olin","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cgh.2014.07.058_bib25","series-title":"Decision modelling for\u00a0health economic evaluation: Oxford handbooks in health economic evaluation","first-page":"77","author":"Briggs","year":"2006"},{"key":"10.1016\/j.cgh.2014.07.058_bib26","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/gutjnl-2011-301133","article-title":"Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?","volume":"61","author":"Beaugerie","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2014.07.058_bib27","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/MEG.0b013e32834b9544","article-title":"Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for\u00a0Crohn's disease","volume":"23","author":"Lin","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2014.07.058_bib28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2014.07.058_bib29","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/ibd.21839","article-title":"Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease","volume":"18","author":"Pariente","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.07.058_bib30","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/j.gastro.2013.07.035","article-title":"Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study","volume":"145","author":"Khan","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.07.058_bib31","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn\u2019s disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.07.058_bib32","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.07.058_bib33","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.07.058_bib34","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2014.07.058_bib35","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2014.07.058_bib36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.07.058_bib37","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S1873-9946(14)60099-4","article-title":"Adalimumab monotherapy versus combination therapy with adalimumab and immunomodulators for Crohn's disease: a meta-analysis","volume":"8","author":"Kopylov","year":"2014","journal-title":"J\u00a0Crohn's Colitis"},{"key":"10.1016\/j.cgh.2014.07.058_bib38","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/S0016-5085(13)60637-X","article-title":"Impact of concomitant immunomodulator treatment on efficacy and safety of anti-TNF therapy in Crohn's disease: a meta-analysis of placebo controlled trials with individual patient-level data","volume":"144","author":"Jones","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.07.058_bib39","doi-asserted-by":"crossref","first-page":"S773","DOI":"10.1016\/S0016-5085(11)63209-5","article-title":"Safety of infliximab and other Crohn's disease therapies: Treat\u2122 registry data with a mean of 5 years of follow-up","volume":"140","author":"Lichtenstein","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.07.058_bib40","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2014.07.058_bib41","unstructured":"SEER. Surveillance, Epidemiology, and End Results database. November 6, 2007. Available at: http:\/\/seer.cancer.gov\/. Accessed."},{"key":"10.1016\/j.cgh.2014.07.058_bib42","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/ibd.22866","article-title":"Prognosis of lymphoma in patients following treatment with 6-mercaptopurine\/azathioprine for inflammatory bowel disease","volume":"18","author":"Sultan","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.07.058_bib43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00054725-199712000-00004","article-title":"An evaluation of utility measurement in Crohn\u2019s disease","volume":"3","author":"Gregor","year":"1997","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.07.058_bib44","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(00)70353-2","article-title":"Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma","volume":"118","author":"Lewis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.07.058_bib45","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.cgh.2012.06.016","article-title":"Effects of cancer treatment on inflammatory bowel disease remission and reactivation","volume":"10","author":"Axelrad","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2014.07.058_bib46","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ajh.21655","article-title":"Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis","volume":"85","author":"Olin","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cgh.2014.07.058_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/pds.2216","article-title":"The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006","volume":"21","author":"Herrinton","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cgh.2014.07.058_bib48","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ibd.20169","article-title":"Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?","volume":"13","author":"Rosh","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.07.058_bib49","series-title":"Decision modelling for\u00a0health economic evaluation: Oxford handbooks in health economic evaluation","first-page":"77","author":"Briggs","year":"2006"},{"key":"10.1016\/j.cgh.2014.07.058_bib50","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1097\/01.MIB.0000437043.36338.21","article-title":"Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model","volume":"19","author":"Scott","year":"2013","journal-title":"Inflamm Bowel Dis"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356514011434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356514011434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:15:40Z","timestamp":1761542140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356514011434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1542356514011434"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2014.07.058","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718530246.793526149","asserted-by":"object"}]},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Benefit-to-Risk Balance of Combining Infliximab With Azathioprine Varies With Age: A Markov Model","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2014.07.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}